Rallybio Corporation (NASDAQ:RLYB) Sees Significant Increase in Short Interest

Rallybio Corporation (NASDAQ:RLYB) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling 1,108,870 shares, a growth of 39.0% from the March 15th total of 797,895 shares. Based on an average trading volume of 108,393 shares, the short-interest ratio is currently 10.2 days. Currently, 23.4% of the company’s shares are sold short.

Institutional Investors Weigh In On Rallybio

Several large investors have recently made changes to their positions in RLYB. XTX Topco Ltd increased its holdings in Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after acquiring an additional 38,205 shares during the last quarter. Susquehanna International Group LLP boosted its stake in Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after purchasing an additional 113,031 shares during the period. Geode Capital Management LLC boosted its stake in Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after purchasing an additional 2,996 shares during the period. Citadel Advisors LLC boosted its position in shares of Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after acquiring an additional 373,821 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after acquiring an additional 120,892 shares during the last quarter. 90.34% of the stock is owned by hedge funds and other institutional investors.

Rallybio Stock Performance

Shares of Rallybio stock traded up $0.05 on Thursday, reaching $8.33. 35,472 shares of the company’s stock were exchanged, compared to its average volume of 124,630. The company has a market capitalization of $44.07 million, a P/E ratio of -3.25 and a beta of -1.20. Rallybio has a 52 week low of $1.95 and a 52 week high of $11.49. The firm’s 50-day moving average is $7.79 and its two-hundred day moving average is $6.10.

Rallybio (NASDAQ:RLYB) last posted its quarterly earnings results on Monday, March 16th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.01. The firm had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.10 million. Rallybio had a negative return on equity of 56.93% and a negative net margin of 1,046.39%. On average, analysts expect that Rallybio will post -1.34 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RLYB has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Rallybio in a report on Monday, December 29th. Wall Street Zen upgraded Rallybio to a “hold” rating in a report on Saturday, March 28th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Rallybio presently has an average rating of “Sell”.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.